INTRODUCTION AND OBJECTIVES: The development of HTLV-1-associated myelopathy (HAM/TSP) in HTLV-1-infected individuals is probably a multi-factor event, in which the immune system plays a crucial role. The efficiency of the host immunity seems to be one of the in vivo determining factors of the proviral load levels and is regulated by genes associated with MHC class I alleles (HLA). Protection or predisposition to HTLV-1-associated diseases according to individual HLA profile was shown in Japanese studies. The present work tested for HLA alleles previously related to protection or susceptibility to HTLV-1-associated myelopathy in a cohort study (GIPH) from Brazil. METHODS: A total of 93 HTLV-1-infected individuals participated in the study, as follows: 84 (90.3%) asymptomatic and 9 (9.7%) with HAM/TSP. Alleles related to protection (A*02, Cw*08) and susceptibility (B*07, Cw*08 and B*5401) were tested by the PCR-SSP method. RESULTS: Allele A*02 was more frequent in the asymptomatic group and in its absence, Cw*07 was correlated with HAM/TSP (P = 0.002). Allele B*5401 was not present in the Brazilian population. Alleles B*07 and Cw*08 were not different between the groups DISCUSSION: The presence of HLA-A2 elicits a stronger cytotoxic response, which is involved in the HTLV-1 proviral load reduction. This study confirmed a tendency of this allele to protect against HAM-TSP. Therefore, A*02 might be of interest for researches involved with HTLV-1 vaccine.
INTRODUCTION AND OBJECTIVES: The development of HTLV-1-associated myelopathy (HAM/TSP) in HTLV-1-infected individuals is probably a multi-factor event, in which the immune system plays a crucial role. The efficiency of the host immunity seems to be one of the in vivo determining factors of the proviral load levels and is regulated by genes associated with MHC class I alleles (HLA). Protection or predisposition to HTLV-1-associated diseases according to individual HLA profile was shown in Japanese studies. The present work tested for HLA alleles previously related to protection or susceptibility to HTLV-1-associated myelopathy in a cohort study (GIPH) from Brazil. METHODS: A total of 93 HTLV-1-infected individuals participated in the study, as follows: 84 (90.3%) asymptomatic and 9 (9.7%) with HAM/TSP. Alleles related to protection (A*02, Cw*08) and susceptibility (B*07, Cw*08 and B*5401) were tested by the PCR-SSP method. RESULTS: Allele A*02 was more frequent in the asymptomatic group and in its absence, Cw*07 was correlated with HAM/TSP (P = 0.002). Allele B*5401 was not present in the Brazilian population. Alleles B*07 and Cw*08 were not different between the groups DISCUSSION: The presence of HLA-A2 elicits a stronger cytotoxic response, which is involved in the HTLV-1 proviral load reduction. This study confirmed a tendency of this allele to protect against HAM-TSP. Therefore, A*02 might be of interest for researches involved with HTLV-1 vaccine.
Authors: Davimar Miranda Borducchi; Maria Gerbase-DeLima; Andrey Morgun; Natalia Shulzhenko; Maria S Pombo-de-Oliveira; José Kerbauy; José Salvador Rodrigues de Oliveira Journal: Br J Haematol Date: 2003-12 Impact factor: 6.998
Authors: Fernando A Proietti; Anna Bárbara F Carneiro-Proietti; Bernadette C Catalan-Soares; Edward L Murphy Journal: Oncogene Date: 2005-09-05 Impact factor: 9.867
Authors: M Osame; R Janssen; H Kubota; H Nishitani; A Igata; S Nagataki; M Mori; I Goto; H Shimabukuro; R Khabbaz Journal: Ann Neurol Date: 1990-07 Impact factor: 10.422
Authors: K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham Journal: Proc Natl Acad Sci U S A Date: 1999-03-30 Impact factor: 11.205
Authors: K J Jeffery; A A Siddiqui; M Bunce; A L Lloyd; A M Vine; A D Witkover; S Izumo; K Usuku; K I Welsh; M Osame; C R Bangham Journal: J Immunol Date: 2000-12-15 Impact factor: 5.422
Authors: Ana Treviño; Jose L Vicario; Mariola Lopez; Patricia Parra; Rafael Benito; Raul Ortiz de Lejarazu; Jose M Ramos; Jorge Del Romero; Carmen de Mendoza; Vincent Soriano Journal: J Neurol Date: 2013-07-09 Impact factor: 4.849